AR110113A1 - Anticuerpo anti-selectina y sus usos - Google Patents
Anticuerpo anti-selectina y sus usosInfo
- Publication number
- AR110113A1 AR110113A1 ARP170103055A ARP170103055A AR110113A1 AR 110113 A1 AR110113 A1 AR 110113A1 AR P170103055 A ARP170103055 A AR P170103055A AR P170103055 A ARP170103055 A AR P170103055A AR 110113 A1 AR110113 A1 AR 110113A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevention
- treatment
- selectin
- selectine
- antibody
- Prior art date
Links
- 230000002265 prevention Effects 0.000 abstract 4
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 abstract 1
- 102100023472 P-selectin Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación se relaciona con el tratamiento o la prevención de trastornos mediados por la selectina P, y con anticuerpos anti-selectina P o fragmentos de unión de estos, para usar en el tratamiento o la prevención de dichos trastornos. En particular, se relaciona con el tratamiento o la prevención de crisis dolorosas asociadas con la drepanocitosis, y con anticuerpos anti-selectina P o fragmentos de unión de estos, para usar en el tratamiento o la prevención de las crisis dolorosas asociadas con la drepanocitosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201618532 | 2016-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110113A1 true AR110113A1 (es) | 2019-02-27 |
Family
ID=62075887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103055A AR110113A1 (es) | 2016-11-03 | 2017-11-03 | Anticuerpo anti-selectina y sus usos |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20200055942A1 (es) |
| AR (1) | AR110113A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250297015A1 (en) * | 2022-05-10 | 2025-09-25 | New York Blood Center, Inc. | Drug conditioning regimen for sickle cell disease |
-
2017
- 2017-11-03 AR ARP170103055A patent/AR110113A1/es unknown
- 2017-11-03 US US16/346,896 patent/US20200055942A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200055942A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120154A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CR20110631A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
| SV2018005661A (es) | Composiciones oligonucleotidicas y sus metodos | |
| MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
| MX2024010175A (es) | Moleculas de anticuerpo contra april y usos de las mismas. | |
| CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| UY36687A (es) | Anticuerpos contra ox40 y sus usos | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX375119B (es) | Anticuerpos contra tau y sus usos. | |
| CL2017000806A1 (es) | Compuestos anti-tnf | |
| CL2017002237A1 (es) | Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. | |
| UY31862A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
| UY36550A (es) | Oligómeros antisentido de tau y sus usos | |
| CO6690781A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| ECSP13012648A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| DOP2015000185A (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| DOP2013000025A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33707A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| UY33826A (es) | Proteínas de unión con dominios trivariables y sus usos | |
| CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
| CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
| CR20160561A (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
| CL2016002281A1 (es) | Anticuerpos de il-21 | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |